Concurrent use of multiple low dose chemotherapy agents with differing mechanisms of action as a strategy vs passive resistance: A pilot study.

David J. Stewart(University of Ottawa), William K. Evans(NHS Forth Valley), C. Cripps(Canadian Partnership Against Cancer), S. Huan, S. Gertler(Ottawa Regional Cancer Foundation), Rakesh Goel(Ottawa Hospital), Jonathan Yau(Ottawa Regional Cancer Foundation), Eva Tomiak(Ottawa Regional Cancer Foundation)
International Journal of Oncology
October 1, 1999
10.3892/ijo.15.4.693
Cited by 3

Related Papers

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer
|Journal of Clinical Oncology|1999|960
Wnt Signaling Pathway in Non-Small Cell Lung Cancer
|JNCI Journal of the National Cancer Institute|2013|659
PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy
|Journal of Clinical Oncology|2016|291
Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study
|The Lancet Oncology|2017|222